Literature DB >> 26921786

Neuropathology in respiratory-related motoneurons in young Pompe (Gaa(-/-)) mice.

Sara M F Turner1, Aaron K Hoyt2, Mai K ElMallah3, Darin J Falk4, Barry J Byrne4, David D Fuller5.   

Abstract

Respiratory and/or lingual dysfunction are among the first motor symptoms in Pompe disease, a disorder resulting from absence or dysfunction of the lysosomal enzyme acid α-glucosidase (GAA). Here, we histologically evaluated the medulla, cervical and thoracic spinal cords in 6 weeks old asymptomatic Pompe (Gaa(-/-)) mice to determine if neuropathology in respiratory motor regions has an early onset. Periodic acid-Schiff (PAS) staining indicated glycogen accumulation was exclusively occurring in Gaa(-/-) hypoglossal, mid-cervical and upper thoracic motoneurons. Markers of DNA damage (Tunel) and ongoing apoptosis (Cleaved Caspase 3) did not co-localize with PAS staining, but were prominent in a medullary region which included the nucleus tractus solitarius, and also in the thoracic spinal dorsal horn. We conclude that respiratory-related motoneurons are particularly susceptible to GAA deficiency and that neuronal glycogen accumulation and neurodegeneration may occur independently in early stage disease. The data support early therapeutic intervention in Pompe disease.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Glycogen; Hypoglossal; Intercostal; Lysosomal storage disease; Neurodegeneration; Phrenic

Mesh:

Substances:

Year:  2016        PMID: 26921786      PMCID: PMC4880056          DOI: 10.1016/j.resp.2016.02.007

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  56 in total

1.  [Pompe disease or type 2 glycogenosis].

Authors:  S Hansoul; B Derkenne; B Daron; H Keutgen; J Senterre
Journal:  Rev Med Liege       Date:  1999-03

2.  EGb761 improves histological and functional recovery in rats with acute spinal cord contusion injury.

Authors:  M Yan; Y-w Liu; W Shao; X-g Mao; M Yang; Z-x Ye; W Liang; Z-j Luo
Journal:  Spinal Cord       Date:  2015-10-20       Impact factor: 2.772

3.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

Authors:  Cathryn Mah; Christina A Pacak; Kerry O Cresawn; Lara R Deruisseau; Sean Germain; Melissa A Lewis; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

4.  Extended use of diaphragm pacing in patients with unilateral or bilateral diaphragm dysfunction: a new therapeutic option.

Authors:  Raymond P Onders; MaryJo Elmo; Cindy Kaplan; Bashar Katirji; Robert Schilz
Journal:  Surgery       Date:  2014-10       Impact factor: 3.982

5.  Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.

Authors:  Mai K ElMallah; Darin J Falk; Michael A Lane; Thomas J Conlon; Kun-Ze Lee; Nadeem I Shafi; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Hum Gene Ther Methods       Date:  2012-04       Impact factor: 2.396

6.  Altered activation of the diaphragm in late-onset Pompe disease.

Authors:  Barbara K Smith; Manuela Corti; A Daniel Martin; David D Fuller; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2015-11-28       Impact factor: 1.931

7.  Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.

Authors:  Robin J Ziegler; Scott D Bercury; Jonathan Fidler; Michael A Zhao; Joseph Foley; Tatyana V Taksir; Susan Ryan; Bradley L Hodges; Ronald K Scheule; Lamya S Shihabuddin; Seng H Cheng
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

8.  Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.

Authors:  Darin J Falk; Cathryn S Mah; Meghan S Soustek; Kun-Ze Lee; Mai K Elmallah; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

9.  Microglia-specific localisation of a novel calcium binding protein, Iba1.

Authors:  D Ito; Y Imai; K Ohsawa; K Nakajima; Y Fukuuchi; S Kohsaka
Journal:  Brain Res Mol Brain Res       Date:  1998-06-01

10.  Nucleus of the solitary tract in the C57BL/6J mouse: Subnuclear parcellation, chorda tympani nerve projections, and brainstem connections.

Authors:  Donald Ganchrow; Judith R Ganchrow; Vanessa Cicchini; Dianna L Bartel; Daniel Kaufman; David Girard; Mark C Whitehead
Journal:  J Comp Neurol       Date:  2014-05-01       Impact factor: 3.215

View more
  22 in total

Review 1.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

2.  Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.

Authors:  Francesco Puzzo; Pasqualina Colella; Maria G Biferi; Deeksha Bali; Nicole K Paulk; Patrice Vidal; Fanny Collaud; Marcelo Simon-Sola; Severine Charles; Romain Hardet; Christian Leborgne; Amine Meliani; Mathilde Cohen-Tannoudji; Stephanie Astord; Bernard Gjata; Pauline Sellier; Laetitia van Wittenberghe; Alban Vignaud; Florence Boisgerault; Martine Barkats; Pascal Laforet; Mark A Kay; Dwight D Koeberl; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Sci Transl Med       Date:  2017-11-29       Impact factor: 17.956

3.  Improved efficacy of a next-generation ERT in murine Pompe disease.

Authors:  Su Xu; Yi Lun; Michelle Frascella; Anadina Garcia; Rebecca Soska; Anju Nair; Abdul S Ponery; Adriane Schilling; Jessie Feng; Steven Tuske; Maria Cecilia Della Valle; José A Martina; Evelyn Ralston; Russell Gotschall; Kenneth J Valenzano; Rosa Puertollano; Hung V Do; Nina Raben; Richie Khanna
Journal:  JCI Insight       Date:  2019-03-07

Review 4.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

5.  The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.

Authors:  Stephan Wenninger; Kristina Gutschmidt; Corinna Wirner; Krisztina Einvag; Federica Montagnese; Benedikt Schoser
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

6.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

7.  Transcriptome assessment of the Pompe (Gaa-/-) mouse spinal cord indicates widespread neuropathology.

Authors:  S M F Turner; D J Falk; B J Byrne; D D Fuller
Journal:  Physiol Genomics       Date:  2016-09-09       Impact factor: 3.107

Review 8.  Pediatric Obstructive Sleep Apnea in High-Risk Populations: Clinical Implications.

Authors:  Mai ElMallah; Evan Bailey; Michelle Trivedi; Ted Kremer; Lawrence M Rhein
Journal:  Pediatr Ann       Date:  2017-09-01       Impact factor: 1.132

9.  Molecular and histologic outcomes following spinal cord injury in spiny mice, Acomys cahirinus.

Authors:  Kristi A Streeter; Michael D Sunshine; Jason O Brant; Aaron G W Sandoval; Malcolm Maden; David D Fuller
Journal:  J Comp Neurol       Date:  2019-12-19       Impact factor: 3.215

10.  Case Studies in Neuroscience: Neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease.

Authors:  David D Fuller; Jorge A Trejo-Lopez; Anthony T Yachnis; Michael D Sunshine; Sabhya Rana; Victoria E Bindi; Barry J Byrne; Barbara K Smith
Journal:  J Neurophysiol       Date:  2021-06-30       Impact factor: 2.974

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.